These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30929534)

  • 41. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
    Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
    Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA; Oladapo AO; Epstein JD; Novack AR; Neufeld EJ; Hay JW
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Evaluation of synovectomy in hemophilic arthropathy follow-up of 26 cases].
    Zheng GZ
    Zhonghua Wai Ke Za Zhi; 1993 Oct; 31(10):585-7. PubMed ID: 8033667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Surgical management of musculoskeletal problems in hemophilia.
    Wilson FC; Mahew DE; McMillan CW
    Instr Course Lect; 1983; 32():233-41. PubMed ID: 6443731
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hemophilic arthropathy. The therapeutic approaches in the clinical picture of hemophilia].
    Ambriz-Fernández R; Rodríguez-Moyado H; Villanueva RM; Muñoz-Olvera R; Gacitua-Zambrano S
    Gac Med Mex; 1991; 127(3):233-9; discussion 239-40. PubMed ID: 1800217
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surgery in hemophilic patients.
    Post M; Telfer MC
    J Bone Joint Surg Am; 1975 Dec; 57(8):1136-45. PubMed ID: 1202004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors.
    Ingerslev J
    Semin Thromb Hemost; 2000; 26(4):425-32. PubMed ID: 11092219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Orthopaedic management of haemophilia arthropathy of the ankle.
    Pasta G; Forsyth A; Merchan CR; Mortazavi SM; Silva M; Mulder K; Mancuso E; Perfetto O; Heim M; Caviglia H; Solimeno L
    Haemophilia; 2008 Jul; 14 Suppl 3():170-6. PubMed ID: 18510538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hemophilic arthropathy.
    Hilgartner MW
    Adv Pediatr; 1974; 21():139-65. PubMed ID: 4614656
    [No Abstract]   [Full Text] [Related]  

  • 50. Aspects of current management: orthopaedic surgery in haemophilia.
    Rodriguez-Merchan EC
    Haemophilia; 2012 Jan; 18(1):8-16. PubMed ID: 21535324
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of joint bleeding in hemophilia.
    Simpson ML; Valentino LA
    Expert Rev Hematol; 2012 Aug; 5(4):459-68. PubMed ID: 22992238
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Management and prevention of recurrent hemarthrosis in patients with hemophilia.
    Dunn AL
    Curr Opin Hematol; 2005 Sep; 12(5):390-4. PubMed ID: 16093785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
    Rodriguez-Merchan EC; Hedner U; Heijnen L; Jimenez-Yuste V; Lee CA; Morfini M; Querol F; Roosendaal G; Santagostino E; Solimeno LP
    Haemophilia; 2008 Nov; 14 Suppl 6():68-81. PubMed ID: 19134036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
    Carr ME; Loughran TP; Cardea JA; Smith WK; Kuhn JG; Dottore MV
    Int J Hematol; 2002 Jan; 75(1):95-9. PubMed ID: 11843300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors.
    Iorio A; Matino D; D'Amico R; Makris M
    Cochrane Database Syst Rev; 2010 Aug; (8):CD004449. PubMed ID: 20687076
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
    Sjamsoedin LJ; Heijnen L; Mauser-Bunschoten EP; van Geijlswijk JL; van Houwelingen H; van Asten P; Sixma JJ
    N Engl J Med; 1981 Sep; 305(13):717-21. PubMed ID: 6790990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic options in the management of hemophilic synovitis.
    Gilbert MS; Radomisli TE
    Clin Orthop Relat Res; 1997 Oct; (343):88-92. PubMed ID: 9345212
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Arthroscopic synovectomy of the knee in hemophilia: 10-to-15 year followup.
    Wiedel JD
    Clin Orthop Relat Res; 1996 Jul; (328):46-53. PubMed ID: 8653977
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Continuous infusion of recombinant factor VIIa: continue or not?
    Ewenstein BM
    Thromb Haemost; 2001 Oct; 86(4):942-4. PubMed ID: 11686349
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.